This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek As Vice-President Of Commercialization For Its Ophthalmology Division

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced the hiring of John Saharek to serve as Vice-President of Commercialization for Ophthalmology.

In his role leading commercialization activities for Imprimis's two lead ophthalmic compounded formulations, Saharek will be chiefly responsible for the "Go Dropless" marketing campaign and related outreach to leading ophthalmologists in the US and abroad.  Imprimis's first compounded formulation is a combination of two or more of Triamcinolone + Moxifloxicin + Vancomycin as an injectable solution.  What makes Imprimis's patent-pending formulation unique is that these formulations are in an injectable solution that can be administered during certain eye surgeries.  No mixing, shaking or adding anything – simply draw and inject.  Imprimis's second compounded drug formulation is a patent-pending lyophilized Epinephrine + Lidocaine or Phenylephrine + Lidocaine.  Imprimis believes these formulations, which are easily reconstituted prior to injection, will offer eye surgeons a stable and reliable source of known mydriatic agents.  In an effort to create awareness about these formulations, Imprimis will soon debut its "Go Dropless" campaign which will encourage ophthalmologists to consider reducing dependence on post-op eye drops, freeing their patients from the expense and inconvenience of eye drops and to simplify their lives with less pharmacy and more control.

"John is an experienced ophthalmology industry leader with a 25 year track record of delivering results to a range of leading companies," said Mark L. Baum, Chief Executive Officer of Imprimis. "John will complete the build out of our commercialization team and will drive our market awareness activities for our innovative ophthalmology solutions.  We are pleased to continue to add new, high-caliber individuals like John to the Imprimis team as we focus on execution and delivering results for our shareholders."

"I am excited to join the Imprimis team, to be able to lead our commercialization efforts at this exciting time," said Saharek. "So many innovative treatments are being developed for patients through the clinical interaction between pharmacists and physicians. It is an honor to help Imprimis take its unique patent-pending innovations to a broader set of patients across the country. Patients deserve and expect personalized medicine. We can deliver that care in a way that serves our patients, our physician and pharmacist partners, and our shareholders."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs